Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment-Reference-Cited by-同舟云学术

Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment

Published:2012-12 Issue:6 Volume:34 Page:722-728
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

D'Avolio Antonio,Ciancio Alessia,Siccardi Marco,Smedile Antonina,Simiele Marco,Cusato Jessica,Baietto Lorena,Marucco Diego Aguilar,Cariti Giuseppe,Calcagno Andrea,Gonzalez de Requena Daniel,Sciandra Mauro,Troshina Giulia,Caviglia Gian Paolo,Bonora Stefano,Rizzetto Mario,Di Perri Giovanni

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference47 articles.

1. . Diagnosis, management, and treatment of hepatitis C: an update.;Ghany;Hepatology,2009

2. Natural history of hepatitis C.;Thomas;Clin Liver Dis,2005

3. . Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes.;Montes-Cano;Hepatology,2010

4. . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.;Hadziyannis;Ann Intern Med,2004

5. . Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.;Jacobson;Hepatology,2007

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection;Antimicrobial Agents and Chemotherapy;2024-09-04

2. Synthesis, characterization, DFT studies, and molecular modeling of hydrazinelidene‐3‐oxo‐3‐(p‐olyl) propanal derivatives as potential candidate for Hepatitis B and C treatment;Vietnam Journal of Chemistry;2022-12

3. Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients;Infection, Genetics and Evolution;2018-06

4. Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study;Journal of Antimicrobial Chemotherapy;2018-03-02

5. Impact of vitamin D receptor and binding protein gene polymorphisms in clinical and laboratory data of HCV patients;Medicine;2018-02